Hepatic Encephalopathy Stage 2, Hepatic Encephalopathy Stage 3, Hepatic Encephalopathy Stage 4
Conditions
Keywords
Lactulose / therapeutic use, Liver Cirrhosis / drug therapy, Ornithine, Aspartic Acid / therapeutic use, Liver Cirrhosis / complications, Hepatic Encephalopathy / drug therapy*, Polyethylene Glycols / therapeutic use*, Gastrointestinal Agents / therapeutic use*
Brief summary
The goal of this clinical trial is to compare the efficacy of L-ornithine L-aspartate and Polyethylene Glycol in Cirrhotic Patients with Overt Hepatic Encephalopathy. Participants will be asked to fill out a few questions on proforma that will obtain demographic information as well as information relating to the patient's health. Treatments that they will receive after inclusion in the study, will be the standard treatment (Lactulose) along with additional medication as part of our research (LOLA or Polyethylene glycol).
Detailed description
This is a randomized control trial with the following objectives * what is the efficacy of add-on LOLA therapy in patients of overt HE (Grade II and above) against the standard-of-care arm * what is the efficacy of adding on polyethylene glycol (PEG) in overt HE (Grade II and above) against the standard-of-care arm Randomization will be done using card randomization. three different color-coded cards will be kept. Any card will be randomly picked for the patient fulfilling inclusion criteria and will be treated according to the allocated treatment arm mentioned on the card Patients will be diagnosed on the basis of Modified West Haven Criteria. For diagnosis and prognosis, the following tools will be used: * Modified West Haven criteria and Glasgow coma scale will be used to assess the mental state. * CLIF-C ADs and CLIF SOFA score will be used as a prognostic score for predicting mortality in hospitalized patients. * Overt HE patients will be graded using the Hepatic encephalopathy grading instrument (HEGI). * Child-Pugh classification and MELD scoring will be used to assess the severity of chronic liver disease and cirrhosis. Written informed consent will be obtained from the immediate attendant of the patient. All ethical considerations will be followed. Our research has been approved by Jinnah Sindh Medical University, Karachi. For this approval, the investigators have made every effort to ensure the confidentiality of research data collected from all our participants in this survey. The information collected will be stored with the investigators only in the form of de-identified information and will be retained in a secure place under lock and key. Any results that will be generated will be presented on a collective basis, and will not contain the participant's name or any other personal details. Data entry and analysis will be done using SPSS Software version 23. Study analysis will be done using the principle of intention to treat. Primary and secondary outcomes will be studied among intervention and standard-of-care groups at a Confidence Interval of 95%. The chi-square test will be used to find the association of independent variables like age, gender, and HE grades with interventional therapies. Independent t-test will be used to compare mean scores between groups.
Interventions
280g/ 24 hours for 5 days
60-120 ml per day for 5 days
30g/24 hours in 3 divided doses for 5 days
Sponsors
Jinnah Postgraduate Medical Centre
Study design
Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Masking description
participants' attendants will also be masked and will give consent for the study in case the participant is admitted to the Intensive care unit and is not mentally stable to give consent.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Admitted cirrhotic patients above 18 years of age, * diagnosed on clinical/ultrasound findings with HE (grade 2 or above) with or without precipitating factors.
Exclusion criteria
* Patients with hepatocellular carcinoma * severe septicemia, * active upper gastrointestinal bleeding and in a state of shock * presence of underlying chronic renal failure (serum creatinine \>1.5 mg/dl) * presence of hepatorenal syndrome * neurodegenerative disease * patients with a head injury and drug intoxication * acute superimposed liver injury * advanced cardiac or pulmonary derangements * end-stage renal disease * pregnant or breastfeeding mothers * patients who are on sedatives, antidepressants, or benzodiazepines
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Patient recovery among all groups through a change in mental state. | Change will be assessed at enrollment. | Change of at least one grade in the mental state based on the modified West Haven criteria and hepatic encephalopathy grading scale. A decrease in the grade will be a better outcome. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| A change in Quality of Life will be assessed through SF-36 | Quality of life will be assessed at 28th day post enrollment. | A change in the quality of life will be assessed using a validated Urdu translation of the Rand Short Form 36 item survey (SF-36 U). The lower the score the more disability. The higher the score the less disability |
| A change in mortality rate | it will be inquired at 7th day post enrollment. | It will be observed through weekly calls and monthly visits. |
Countries
Pakistan
Contacts
Primary ContactZeeshan Ali, FCPS
Backup ContactShamim Kausar, FCPS
Outcome results
None listed